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North CarolinaBackground. The goal of the present study was to es-
timate the rate of local/regional failure (LRF) after
definitive surgical intervention for early-stage non-small
cell lung cancer (NSCLC), without postoperative radio-
therapy, in the era of contemporary imaging and mini-
mally invasive surgical techniques.
Methods. Medical records of patients with early-stage
NSCLC (pathologic T1-4, N0-1) who underwent lobec-
tomy, sleeve lobectomy, bilobectomy, or pneumonec-
tomy, with or without adjuvant chemotherapy, between
2007 and 2015, were retrospectively reviewed. LRF was
defined as recurrence at the ipsilateral lung, bronchial
stump, mediastinum, chest wall, or supraclavicular
region. The Kaplan-Meier method was used to estimate
time to LRF, with patients censored at death, and log-rank
tests were used for comparisons. A two-sided p value of
less than 0.05 was considered significant.
Results. Included were 217 patients (median age, 65
years). Preoperative staging with positron emission
tomography/computed tomography was performed in 89%Accepted for publication March 26, 2018.
Presented at the Poster Session of the Multidisciplinary Symposium in 
Thoracic Oncology of the International Association for the Study of Lung 
Cancer, Chicago, IL, Sept 14–16, 2017.
Address correspondence to Dr Judy, University of North Carolina 
Hospitals, 101 Manning Dr, CB #7512, Chapel Hill, NC 27599; email: 
gregory.judy@unchealth.unc.edu.of patients, mediastinoscopy was performed in 42%, and
video-assisted thoracoscopic surgery was performed in
51%. At a median follow-up of 36 months (range, 1 to 120
months), the 5-year estimatedLRFwas26%(95%confidence
interval, 20% to 35%). LRF rates were not significantly
different in those with and without staging positron emis-
sion tomography/computed tomography (hazard ratio, 1.52;
p [ 0.43) and those with video-assisted thoracoscopic sur-
gery versus open thoracotomy (hazard ratio, 1.00; p[ 0.99).
Conclusions. Despite contemporary staging procedures
and surgical techniques for early-stage NSCLC, LRF
occurs in approximately 1 of 4 patients. The observed
rates of LRF are similar to those reported more than a
decade ago, suggesting that local/regional control remains
a persistent problem. The use of additional local treat-
ments, such as radiotherapy, should be reevaluated to
further improve outcomes.he most accepted approach for early-stage non-smallTcell lung cancer (NSCLC) is surgical resection, with or
without adjuvant chemotherapy. Significant improve-
ments in surgical technique in the last 20 years, including
anatomic lung resections (eg, lobectomy and segmentec-
tomy) and increased use of minimally invasive surgical
techniques (eg, video-assisted thoracoscopic surgery
[VATS]), have improved short-term surgical outcomes
(ie, postoperative complications) [1]. In addition, im-
provements in preoperative imaging with positron
emission tomography (PET) and computed tomography(CT) may have allowed for better selection of patients
more likely to have true early-stage disease.
With both improvements, one might therefore presume
that oncologic outcomes will improve as well. Better
preoperative visualization of the anatomic tumor location
could potentially allow for more a accurate operation and
pathologic assessments (eg, margin status), and perhaps
thoracoscopic approaches might potentially provide
better intraoperative visualization of tumor extent (eg,
less intraoperative bleeding, less physiologic stress
enabling longer procedure times, and magnified views of
the operative site). In multiple studies of patients resected
for early-stage disease from 1966 to 2006, crude rates of
local/regional failure (LRF) were reported in the range of
6% to 28% for N0 disease [2–13] and 18% to 49% for N1
disease [6, 12, 14–19].
In a previous study of patients undergoing resection
between 1996 and 2006 at our institution, similar rates of
LRF (5-year LRF of 24%) were noted [20]. The goal of thehttps://doi.org/10.1016/j.athoracsur.2018.03.062
present study was to reassess this question in the present 
era (2007 to 2015) of contemporary imaging with PET/CT 
and minimally invasive surgical techniques with VATS.Material and Methods
Study Design and Patients
This was a single-institution retrospective analysis of 
patients who underwent initial resection for primary 
NSCLC at the University of North Carolina, Chapel Hill, 
North Carolina, from January 2007 through December 
2015. The University of North Carolina Institutional 
Review Board approved this study (16-0096).
Only patients with early-stage NSCLC (pathologic 
T1-4, N0-1, 7th edition American Joint Committee on 
Cancer staging [21]) who underwent anatomic resection 
(eg, lobectomy, sleeve lobectomy, bilobectomy, or pneu-
monectomy), with or without adjuvant chemotherapy,Fig 1. Consolidated Standards of Reporting Trials diagram. (NSCLC ¼ no
UNC ¼ University of North Carolina.)were included. Excluded from our analysis were patients
who underwent less than an anatomic complete resection
(eg, wedge resection), whose mediastinal lymph nodes
were not sampled at preresection mediastinoscopy or at
the time of the operation, had advanced disease (eg, N2/
N3 nodes, M1 disease), positive surgical margins, histol-
ogies other than adenocarcinoma, squamous cell carci-
noma, or large cell carcinoma (eg, small cell, carcinoid,
sarcomas, or metastases), treated with neoadjuvant
chemotherapy, radiotherapy (RT), or both, treated with
postoperative RT (with or without chemotherapy), had
less than 1 month of follow-up, or whose failure status
was unknown. A Consolidated Standards of Reporting
Trials diagram is shown in Figure 1.
Data Extraction
The medical records, pertinent radiologic imaging,
operative notes, and pathology reports were reviewed ton-small cell lung carcinoma; SCC ¼ squamous cell carcinoma;
characterize the patient’s clinical and demographic in-
formation, review preoperative imaging and staging
procedures (including tumor location), acquire surgical
and pathologic details (including surgical technique,
tumor histology, margins, invasion, and pathologic stage),
characterize adjuvant therapy, and classify postoperative
patterns of failure. Tumor location was collected and
defined as central or peripheral according to the distance
from the proximal bronchial tree as measured on pre-
operative chest CT. Central location was defined as tumor
within 2 cm of the proximal bronchial tree, which was
defined by Timmerman and colleagues [22] as the distal 2
cm of trachea, carina, and major lobar bronchi.
Postoperative follow-up typically included clinical
examinations and repeat chest imaging (mostly CT scan)
every 3 to 6 months for the first 3 to 5 years. Adjuvant
chemotherapy was included in the analysis and typically
administered to patients with stage IB or higher disease
and an acceptable performance status.
Disease Failure
The presence and site of a failure was obtained from the
medical records. LRF was classified as the ipsilateral lung,
stump, mediastinum, chest wall, or supraclavicular
region. Nodal failure was defined as a new or enlarging
lymph node 1 cm or larger on short-axis CT or hyper-
metabolic on PET and was consistent with disease failure
on subsequent follow-up appointments. Treatment fail-
ure was defined as local/regional, distant, or both. The
date of failure, date of death (if applicable), and whether
the recurrence was proven by a biopsy specimen was also
collected.
Statistical Methods
Descriptive statistics were used to describe the patient
characteristics, surgical details, and pathologic details.
The primary outcome of interest was the time to LRF
measured from the date of the operation. Patients who
did not experience LRF were censored at the last follow-
up or death. The Kaplan-Meier method was used to
estimate the cumulative incidence rate, and the log-rank
test was used to compare cumulative incidence curves.
A two-sided p value of less than 0.05 was considered
significant. The Cox regression model was used to esti-
mate the hazard ratio (HR). A sensitivity analysis treating
death as a competing risk was explored using the Fine
and Gray method; however, due to few deaths, results
were similar. SAS 9.4 software (SAS Institute Inc, Cary,
NC) was used for all analyses.Results
During the study period, 515 patients underwent an
initial operation for a primary diagnosis of NSCLC, of
which 217 met inclusion criteria and were included in the
final analysis. The median follow-up from the operation
was 36 months (range, 1 to 120 months). Patients were a
median age of 65 years (range, 42–90 years), 75% were
male, 71% were white, and 87% had a tobacco history
greater than 10 pack-years.Preoperative staging with chest CT was performed in
25 patients (11%) and with PET/CT in 192 (89%).
Mediastinoscopy was performed in 90 patients (41%): 34
preoperatively and 56 during resection. The surgical
procedure was VATS in 51% of patients, and 92%
underwent a lobectomy. The pathologic stage was I in
74% of patients, and 80% of patients did not receive
adjuvant chemotherapy. Most tumors were peripherally
located (74%), and the mean distance to the closest
positive margin was 2.2 cm (median, 1.9 cm; range, 0.1
to 9.0 cm). The margin distance was less than the
maximum tumor diameter in 56% of cases. Additional
patient, surgical, and pathologic details are presented in
Table 1.
The 5-year estimated LRF for the entire cohort was
26% (95% confidence interval, 20% to 35%; Fig 2). Local
failures occurred in 42 patients (19%), with 74%
confirmed by biopsy specimen, and the rest were
confirmed with CT (18%) or PET/CT (9%). Distant fail-
ures occurred in 6 patients, all of which were proven by a
biopsy specimen. The 5-year estimated LRF for patients
with pathological stage T1 N0 and T2 N0 are 18% and
26%, respectively (the other subgroups were not large
enough to perform the calculation). For the T1 N0 sub-
group, local failures occurred in 13 patients (31%), with
92% confirmed by biopsy specimen. For the T2 N0 sub-
group, local failures occurred in 14 patients (33%), with
79% confirmed by biopsy specimen. Most of the local
failures occurred in the ipsilateral lung (7% for both
T1/T2 N0) and mediastinum (7% T1 N0, 5% T2 N0),
followed by the contralateral lung (2% T1 N0, 5% T2 N0),
staple line (5% T1 N0, 2% T2 N0), stump (2% for both
T1/T2 N0), chest wall (0% T1 N0, 2% T2 N0), and
multiple sites (5% T1 N0, 10% T2 N0).
The risk of LRF was higher in men than in women (34%
vs 17%; HR, 2.10; p ¼ 0.03), in those with lymphovascular
space invasion (38% vs 25%; HR, 2.33; p¼ 0.03), T3 and T4
disease compared with T1 and T2 (64% vs 23%; HR, 3.35;
p ¼ 0.001), N1 disease compared with N0 (47% vs 24%;
HR, 2.19; p ¼ 0.03), and disease stage II and III compared
with stage I (42% vs 21%; HR, 2.19; p ¼ 0.01; Table 2). A
higher risk for LRF was not significantly associated with
VATS versus open surgical technique (27% vs 26%; HR,
1.00; p ¼ 0.99), preoperative imaging with PET/CT versus
no PET/CT (32% vs 26%; HR 1.52, p¼ 0.42), central versus
peripheral tumor location (31% vs 24%; HR, 1.41, p ¼
0.29), or margin status of 2 cm or less versus more than
2 cm (30% vs 23%; HR 1.32, p ¼ 0.40; Figs 3 and 4, Table 2).Comment
Resection alone continues to be the most accepted
approach for patients with early-stage NSCLC. The
main mode of recurrence in these patients has tradi-
tionally been thought to be distant because local control
rates of 80% or more have been reported [7] and adju-
vant chemotherapy has been shown to improve overall
survival in select cases [23, 24]. Nevertheless, the esti-
mated 5-year LRF rate in the current series is 26% and is
similar to 5-year LFR rate of 24% reported from our
Table 1. Patient and Tumor Characteristics
Characteristica Result (n ¼ 217)
Age, years
Mean 64










10 pack-years 8 (4)
>10 pack-years 189 (87)
Preoperative imaging












During resection 56 (62)
No 127 (59)
N1 lymph node sampling
Yes 215 (99)
No 2 (1)








Right upper lobe 86 (39)
Right middle lobe 10 (4)
Right lower lobe 36 (17)
Right middle, right lower lobe 3 (1)
Right upper, right middle lobe 4 (2)
Left upper lobe 47 (22)
Left lower lobe 30 (14)
Left lower, left upper lobe 1 (1)
Histologyb
Adenocarcinoma 134 (62)
Squamous cell carcinoma 75 (35)
Large cell 7 (3)
(Continued)
Table 1. Continued
Characteristica Result (n ¼ 217)
Pathologic size of lesion, cm
Mean 3.1














Distance to closest surgical margin,b cm
Mean 2.2














a Categoric data are shown as number (%) and continuous data as
indicated. b No malignancy in 1 specimen.
CT ¼ computed tomography; PET ¼ positron emission tomogra-
phy; VATS ¼ video assisted thoracoscopic surgery.institution in previous years (1996 to 2006), as well as
other prospective and retrospective studies [6, 14], and
suggests that local/regional control remains a persistent
challenge.
Direct LRF comparisons between studies are difficult
given the variability in the definition of a local failure in
the literature. Some studies define ipsilateral medias-
tinum as a local recurrence but not contralateral medi-
astinum [24], and others report isolated local failures
defined as the ipsilateral lung or mediastinum, or both
[3, 7]. In addition, local recurrence may be underreported
or missed if it is not the primary end point of a study, is
not thoroughly looked for, or is only scored in the absence
of a distant recurrence [7].
Surgical techniques have evolved over time, with VATS
becoming more common during the last decade. This
significant change in technique has led to improvements
Fig 2. Cumulative incidence curve shows overall time to local/
regional failure (LRF): cause-specific rate of 26% at 5 years and
competing risk-adjusted rate of 25% at 5 years.









Male vs female 2.10 1.08–4.10 0.03
Histology
Squamous vs nonsquamous 1.63 0.89–2.99 0.11
Surgical technique
VATS vs open 1.00 0.55–1.84 0.99
Lymphovascular space
invasion
Yes vs no 2.33 1.08–5.05 0.03
Visceral pleural invasion
Yes vs no 1.20 0.50–2.85 0.68
Margin status
2 cm vs >2 cm 1.32 0.69–2.53 0.40
Margin distance > max tumor
diameter
Yes vs no 0.53 0.23–1.06 0.07
Tumor location
Central vs peripheral 1.41 0.74–2.70 0.29
T stage
T3-4 vs T1-2 3.35 1.55–7.25 0.001
N stage
N1 vs N0 2.19 1.05–4.58 0.03
Stage
II-III vs I 2.19 1.19–4.03 0.01
Imaging
PET/CT vs no PET/CT 1.52 0.54–4.26 0.43
CI ¼ confidence interval; PET/CT ¼ positron emission tomography/
computed tomography; VATS ¼ video-assisted thoracoscopic
surgery.
Fig 3. Cumulative incidence curve shows time to local/regional
failure (LRF) in patients who had a preoperative staging with
positron emission tomography/computed tomography scan (PET/CT)
scan compared with those who did not have a PET/CT scan (32% vs
26% at 5 years, p ¼ 0.42).in short-term surgical outcomes. Compared with open
lobectomy, VATS lobectomy has similar oncologic out-
comes and an arguably equivalent assessment of
mediastinal lymph node stations with lower complication
rates and length of hospital stay [25–27].
Imaging has also evolved, allowing improvements in
preoperative staging with the addition of PET, because
adding PET to preoperative CT scans improves theFig 4. Cumulative incidence curve shows time to local/regional
failure (LRF) in patients who underwent video-assisted thoracoscopic
surgery (VATS) compared with open thoracotomy (27% vs 26% at


















































sensitivity and specificity compared with CT scans alone
[28, 29]. PET/CT also has a high negative predictive value
(95%) and positive predictive value (74%) for mediastinal
lymph node detection, which can be used advantageously
when selecting patients for invasive procedures (eg,
mediastinoscopy). In addition, the accuracy of nodal
sampling during an anatomic resection can affect staging,
adjuvant therapy recommendations, and oncologic out-
comes; for example, inaccurate staging of N1 nodal stations
or undefined N1 stations has been associated with higher
LRF rates [30]. However, despite these improvements in
surgical approach and preoperative imaging, LRF remains
a significant problem in these pa-tients. Because lung
cancer is a highly invasive and aggressive disease, our
advances (eg, in imaging) are likely relatively modest
“from the perspective of the tumor,” and microscopic
tumor infiltration into local/regional tissues remains
relatively prevalent despite a negative PET scan [31].
Compared with the University of North Carolina study
of patients who underwent resection from 1996 to 2006,
the current more modern cohort was more likely to un-
dergo PET/CT for preoperative staging (89% vs 34%) and
VATS (51% vs 8%), indicating a shift in preoperative
workup and surgical technique. Nevertheless, the LRF
rates appear similar in the two cohorts. The fraction of
patients pathologically staged was similar in the two
groups (26% in the current study versus 24% in the prior
study), suggesting that this comparison is reasonable.
The use of adjuvant RT in early-stage NSCLC has fallen
out of favor, an appropriate change in practice driven
largely by the detriment in survival seen in the meta-
analysis [32, 33]. Postoperative RT as delivered in the
trials included in the meta-analysis is clearly potentially
toxic. Nonetheless, given the apparent persistent pres-
ence of LRFs in these patients, the potential role of
adjuvant postoperative RT using modern techniques
might be worth reexamining.
One factor that has been hypothesized as contributing to
the toxic effects of RT seen in the meta-analysis is RT field
size. RT planning used in the studies included in the meta-
analysis predated the three-dimensional era, so fields were
large; for example, including the entire mediastinum, with
or without the ipsilateral supraclavicular region and
contralateral hilum. Advances in radiation oncology, such
as three-dimensional planning and intensity modulated
RT, allow for more conformal dose delivery that better
targets the high-risk areas. Indeed, two small studies
published after the initial meta-analysis using smaller
three-dimensional–planned RT fields, better targeting the
areas at risk, suggested improved oncologic outcomes with
postoperative RT [8, 34].
A number of factors have been associated with an
increased risk of LRF, including type of operation (eg,
nonanatomic sublobar resection), positive margins, larger
tumor size, limited mediastinal lymph node sampling, and
the presence of lymphovascular space invasion or visceral
pleural invasion [6, 7, 10, 14, 17, 20, 24, 35–37]. We  found
similar findings with gender (men), lymphovas-cular space
invasion, higher T stage (T3, T4), N1 disease,and higher overall stage (stage II to III) being associated
with a higher rate of LRF. However, even in the “lower-
risk” patients (eg, T1 N0, T2 N0), LRF remains an issue in
the present study (18% and 26%, respectively) and in
others’ series (T1-2 N0, 5-year LRF 19%) [20].
Negative surgical margins but with a margin distance
of less than 1.5 to 2 cm has also been associated with a
higher risk of LRF [38, 39], with some reports showing
worse local control if the margin distance is less than the
maximum tumor diameter [38, 39]. Consistent with the
literature, we found a nearly significant increase in LRF in
patients who did not have a margin distance greater than
the maximum tumor diameter and nonsignificant trends
in those with smaller margins and in those with central
tumors [38, 39].
The results presented highlight that LRF remains a
clinical problem. This, coupled with improvements in RT
planning and delivery techniques, might make it
reasonable to reconsider the role of adjuvant post-
operative RT in these patients to help improve local/
regional control and survival. Although challenging, a
prospective trial to restudy the role of postoperative RT in
this setting is reasonable to consider. Two modest-sized
studies of postoperative conformal RT in early-stage
lung cancer have suggested improvements in local
control and survival [8, 34], suggesting that a larger study
might be worthwhile.
This study has several limitations. First, the data
extraction was retrospective; however, we were able to
gather the desired clinical and pathologic factors from the
medial records. Our hospital has had an electronic
medical record for approximately 22 years, and the
pathology and operative notes were thus readily avail-
able. Further, the retrospective nature would likely tend
to underreport LRFs, and the noted LRF rates might thus
be considered as minimum values.
Second, patients were not evaluated in a consistent
manner after the operation (eg, postoperative scans were
not always done regularly). Again, this issue would tend
to underestimate the apparent rates of LRF, and we thus
believe our conclusions remain valid.
Third, the patients studied were treated during a
10-year interval. Changes in surgical, staging, and treat-
ment techniques during the study period may have
influenced the LRF rates. However, broadly speaking, the
LRF rates in the 1996 to 2006 cohort and in the 2007 to
2015 cohorts were similar, suggesting that pooling
of patients during this period may be reasonable.
Further, all of these patients were treated in a single
institution, thus perhaps reducing interprovider factors
that might, over time, confound the outcomes.
Fourth, the cohort consists of a heterogeneous patient
population, and thus, results for our largest subset of the
earliest stage cases (ie, T1-2 N0) are reported separately,
with higher stages excluded.
Fifth, fewer than three mediastinal lymph node stations
were sampled during the operation in 55% of patients.
This may have contributed to the elevated LRF rate,
because several consensus groups have recommended
that at least three stations be sampled [40].
Finally, our sample size was smaller compared with
prior studies, which limited our analysis of LRF rates in
patient subgroups; however, in the subgroups with
enough patients to analyze (T1 N0 and T2 N0), LRF rates
were similar to our 1996 to 2006 cohort; again, suggesting
that pooling of patients over this time period may be
reasonable.
Conclusion
Despite the use of contemporary staging procedures and
surgical techniques for early-stage NSCLC, LRF occurs in
approximately 1 of 4 patients. The observed rates of LRF
are similar to those that were reported more than a
decade ago, suggesting LRF remains a persistent prob-
lem. The use of additional local treatments, such as
conformal RT, should be reevaluated as a means to
further improve outcomes.References
1. Paoletti L, Pastis NJ, Denlinger CE, Silvestri GA. A decade of
advances in treatment of early-stage lung cancer. Clin Chest
Med 2011;32:827–38.
2. Lafitte JJ, Ribet ME, Prevost BM, Gosselin BH, Copin MC,
Brichet AH. Postresection irradiation for T2 N0 M0 non-
small cell carcinoma: a prospective, randomized study. Ann
Thorac Surg 1996;62:830–4.
3. Feld R, Rubinstein LV, Weisenberger TH. Sites of recurrence
in resected stage I non-small-cell lung cancer: a guide for
future studies. J Clin Oncol 1984;2:1352–8.
4. Kato H, Ichinose Y, Ohta M, et al. A randomized trial of
adjuvant chemotherapy with uracil-tegafur for adenocarci-
noma of the lung. N Engl J Med 2004;350:1713–21.
5. Bedini AV, Cataldo I, Valente M, Ravasi G. Five-year
recurrence probabilities in 330 patients curatively resected
for stage Ia bronchogenic carcinoma. Tumori 1987;73:131–7.
6. Lardinois D, Suter H, Hakki H, Rousson V, Betticher D,
Ris HB. Morbidity, survival, and site of recurrence after
mediastinal lymph-node dissection versus systematic sam-
pling after complete resection for non-small cell lung cancer.
Ann Thorac Surg 2005;80:268–74; discussion 274–5.
7. Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy
versus limited resection for T1 N0 non-small cell lung cancer.
Lung Cancer Study Group. Ann Thorac Surg 1995;60:615–22;
discussion 622–3.
8. Trodella L, Granone P, Valente S, et al. Adjuvant radio-
therapy in non-small cell lung cancer with pathological stage
I: definitive results of a phase III randomized trial. Radiother
Oncol 2002;62:11–9.
9. Sawyer TE, Bonner JA, Gould PM, Deschamps C, Lange CM,
Li H. Patients with stage I non-small cell lung carcinoma at
postoperative risk for local recurrence, distant metastasis,
and death: implications related to the design of clinical trials.
Int J Radiat Oncol Biol Phys 1999;45:315–21.
10. Harpole DH Jr, Herndon JE 2nd, Young WG Jr, Wolfe WG,
Sabiston DC Jr. Stage I nonsmall cell lung cancer. A multi-
variate analysis of treatment methods and patterns of
recurrence. Cancer 1995;76:787–96.
11. Martini N, Bains MS, Burt ME, et al. Incidence of local
recurrence and second primary tumors in resected stage I
lung cancer. J Thorac Cardiovasc Surg 1995;109:120–9.
12. Immerman SC, Vanecko RM, Fry WA, Head LR, Shields TW.
Site of recurrence in patients with stages I and II carcinoma
of the lung resected for cure. Ann Thorac Surg 1981;32:23–7.
13. Gauger J, Patz EF Jr, Coleman RE, Herndon JE 2nd. Clinical
stage I non-small cell lung cancer including FDG-PET
Imaging: sites and time to recurrence. J Thorac Oncol
2007;2:499–505.14. Kelsey CR, Marks LB, Hollis D, et al. Local recurrence after
surgery for early stage lung cancer: an 11-year experience
with 975 patients. Cancer 2009;115:5218–27.
15. Stephens RJ, Girling DJ, Bleehen NM, Moghissi K,
Yosef HM, Machin D. The role of post-operative radio-
therapy in non-small-cell lung cancer: a multicentre rando-
mised trial in patients with pathologically staged T1-2, N1-2,
M0 disease. Medical Research Council Lung Cancer Work-
ing Party. Br J Cancer 1996;74:632–9.
16. Feng QF, Wang M, Wang LJ, et al. A study of postoperative
radiotherapy in patients with non-small-cell lung cancer:
a randomized trial. Int J Radiat Oncol Biol Phys 2000;47:
925–9.
17. Sawyer TE, Bonner JA, Gould PM, et al. Factors predicting
patterns of recurrence after resection of N1 non-small cell
lung carcinoma. Ann Thorac Surg 1999;68:1171–6.
18. Luzzi L, Voltolini L, Campione A, et al. Pneumonectomy vs
lobectomy in the treatment of pathologic N1 NSCLC: could
the type of surgical resection dictate survival? J Cardiovasc
Surg (Torino) 2003;44:119–23.
19. Matsuoka K, Sumitomo S, Misaki N. Prognostic factors in
patients with pathologic T1-2N1M0 disease in non-small cell
carcinoma of the lung. J Thorac Oncol 2007;2:1098–102.
20. Saynak M, Veeramachaneni NK, Hubbs JL, et al. Local fail-
ure after complete resection of N0-1 non-small cell lung
cancer. Lung Cancer 2011;71:156–65.
21. Edge S, Byrd DR, Comptom CC, Fritz AG, Greene FL,
Trotti A 3rd (eds). AJCC cancer staging handbook: from the
AJCC cancer staging manual. 7th edition. New York:
Springer; 2009.
22. Timmerman R, Paulus R, Galvin J, et al. Stereotactic body
radiation therapy for inoperable early stage lung cancer.
JAMA 2010;303:1070–6.
23. Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based
adjuvant chemotherapy in patients with completely resected
non-small-cell lung cancer. N Engl J Med 2004;350:351–60.
24. Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinor-
elbine plus cisplatin versus observation in patients with
completely resected stage IB-IIIA non-small-cell lung cancer
(Adjuvant Navelbine International Trialist Association
[ANITA]): a randomised controlled trial. Lancet Oncol 2006;7:
719–27.
25. Rueth NM, Andrade RS. Is VATS lobectomy better: peri-
operatively, biologically and oncologically? Ann Thorac Surg
2010;89:S2107–11.
26. Chen FF, Zhang D, Wang YL, Xiong B. Video-assisted thor-
acoscopic surgery lobectomy versus open lobectomy in
patients with clinical stage non-small cell lung cancer: a
meta-analysis. Eur J Surg Oncol 2013;39:957–63.
27. D’Amico TA, Niland J, Mamet R, Zornosa C, Dexter EU,
Onaitis MW. Efficacy of mediastinal lymph node dissection
during lobectomy for lung cancer by thoracoscopy and
thoracotomy. Ann Thorac Surg 2011;92:226–31; discussion
231–2.
28. Pieterman RM, van Putten JW, Meuzelaar JJ, et al. Preoper-
ative staging of non-small-cell lung cancer with positron-
emission tomography. N Engl J Med 2000;343:254–61.
29. Vansteenkiste JF, Stroobants SG, De Leyn PR, et al. Lymph
node staging in non-small-cell lung cancer with FDG-PET
scan: a prospective study on 690 lymph node stations from
68 patients. J Clin Oncol 1998;16:2142–9.
30. Saynak M, Hubbs J, Nam J, et al. Variability in defining T1N0
non-small cell lung cancer impacts locoregional failure
and survival. Ann Thorac Surg 2010;90:1645–9; discussion
1649–50.
31. Yilmaz U, Wong TZ, Marks LB. How good is PET in
detecting previously-occult metastatic cancer at diagnosis?
Int J Radiat Oncol Biol Phys 2017 Nov 15 [in press accepted
manuscript].
32. Postoperative radiotherapy in non-small-cell lung cancer:
systematic review and meta-analysis of individual patient
data from nine randomised controlled trials. PORT
Meta-analysis Trialists Group. Lancet 1998;352:257–63.
33. Burdett S, Rydzewska L, Tierney J, et al. Postoperative
radiotherapy for non-small cell lung cancer. Cochrane
Database Syst Rev 2005:CD002142.
34. Mayer R, Smolle-Juettner FM, Szolar D, et al. Postoperative
radiotherapy in radically resected non-small cell lung cancer.
Chest 1997;112:954–9.
35. Lee JH, Machtay M, Kaiser LR, et al. Non-small cell lung
cancer: prognostic factors in patients treated with surgery
and postoperative radiation therapy. Radiology 1999;213:
845–52.
36. Warren WH, Faber LP. Segmentectomy versus lobectomy in
patients with stage I pulmonary carcinoma. Five-year sur-
vival and patterns of intrathoracic recurrence. J Thorac
Cardiovasc Surg 1994;107:1087–93; discussion 1093–4.37. Hsu HC, Wang CJ, Huang EY, Sun LM. Post-operative
adjuvant thoracic radiotherapy for patients with completely
resected non-small cell lung cancer with nodal involvement:
outcome and prognostic factors. Br J Radiol 2004;77:43–8.
38. Sawabata N, Ohta M, Matsumura A, Nakagawa K, et al.
Optimal distance of malignant negative margin in excision of
nonsmall cell lung cancer: a multicenter prospective study.
Ann Thorac Surg 2004;77:415–20.
39. Schuchert MJ, Pettiford BL, Keeley S, et al. Anatomic
segmentectomy in the treatment of stage I non-small cell
lung cancer. Ann Thorac Surg 2007;84:926–32.
40. Ettinger DS, Kris MG. Update: NCCN non-small cell lung
cancer clinical practice guidelines. J Natl Compr Canc Netw
2004;2:9–13.
